Premier Biomedical, Inc. (OTCPK: BIEI)
Health Care · Biotechnology · US
$0.00
-14.29% today · +9.1% 1Y
Premier Biomedical, Inc. (OTCPK: BIEI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.01M and employs 4 people.
Over the last twelve months the share price has gained 9.1%, trading between 0.00 and 0.00.
Tweenvest scores Premier Biomedical, Inc. across four factors: quality 5/100, value 53/100. Its strongest factor is value.
BIEI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.01M
- Revenue (TTM)
- $14.28K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.84
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.69B
- Employees
- 4
- Next earnings
- —
About Premier Biomedical, Inc.
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer’s disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.
- ISIN
- US74048K2033
- Founded
- 2010
- Listed since
- Aug 15, 2012
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.